tickrz reports
  
tickrz rank
D
Bristol-Myers Squibb Co (BMY)
Healthcare | Drug Manufacturers - Major
CEO: Giovanni Caforio
Employees: 25000
bms.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank320Dividend Rank118
Moat Rank349Financial Strength Rank295
Growth Rank374Momentum Rank480
DIVIDEND ANALYSIS
Dividend Yield2.85%
Payout Ratio53.06%
3 yr Dividend Growth2.76%
VALUATION RATIOS
P/E Ratio18.57x
P/B Ratio6.23x
P/S Ratio4.5x
EV/EBITDA Ratio13.31x
FINANCIAL STRENGTH
Piotroski F-Score6
Debt-to-Equity58%
Interest Coverage0x
MOAT
ROE33.19%
ROIC27.2%
Net Margin22.94%
GROWTH
5 yr EPS Growth4.17%
5 yr SPS Growth-1.77%
5 yr BPS Growth0.53%
Bristol-Myers Squibb Co's strong Dividend Rank may warrant a closer look for investors seeking dividend paying stocks
 tickrz summary
Bristol-Myers Squibb Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Bristol-Myers Squibb Co's valuation score is comprised of a P/E ratio of 18.6x, a P/B ratio of 6.2x, a P/S ratio of 4.5x, and an EV/EBITDA ratio of 13.3x. Bristol-Myers Squibb Co ranks 320 out of the S&P 500 constituents on valuation--a relatively weak score.Bristol-Myers Squibb Co ranks 288 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Bristol-Myers Squibb Co is probably not for you.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Bristol-Myers Squibb Co has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 58% and a Moat Rank of 349 translate to an average Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -24.36% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 480. Based on its 12 month stock performance, Bristol-Myers Squibb Co will not appeal to momentum investors.

 yield
 value + yield
Shares currently yield 2.85%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Bristol-Myers Squibb Co ranks 118 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Bristol-Myers Squibb Co.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 4.2% 5 year annualized EPS growth, -1.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 0.5% speak to its relatively poor ranking.

Bristol-Myers Squibb Co (BMY)
Healthcare | Drug Manufacturers - Major
CEO: Giovanni Caforio
Employees: 25000
bms.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio18.57x
P/B Ratio6.23x
P/S Ratio4.5x
EV/EBITDA Ratio13.31x
DIVIDEND ANALYSIS
Dividend Yield2.85%
Payout Ratio53.06%
3 yr Dividend Growth2.76%
FINANCIAL STRENGTH
Piotroski F-Score6
Debt-to-Equity58%
Interest Coverage0x
MOAT
ROE33.19%
ROIC27.2%
Net Margin22.94%
GROWTH
5 yr EPS Growth4.17%
5 yr SPS Growth-1.77%
5 yr BPS Growth0.53%

TICKRZ RANK
Bristol-Myers Squibb Co receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Bristol-Myers Squibb Co's valuation score is comprised of a P/E ratio of 18.6x, a P/B ratio of 6.2x, a P/S ratio of 4.5x, and an EV/EBITDA ratio of 13.3x. Bristol-Myers Squibb Co ranks 320 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Bristol-Myers Squibb Co ranks 288 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a average score, meaning it ranks in the middle of the pack on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Bristol-Myers Squibb Co is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Bristol-Myers Squibb Co has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 0x, a debt/equity ratio of 58% and a Moat Rank of 349 translate to an average Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -24.36% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 480. Based on its 12 month stock performance, Bristol-Myers Squibb Co will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.85%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Bristol-Myers Squibb Co ranks 118 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Bristol-Myers Squibb Co.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the bottom third of S&P500 companies. Its 4.2% 5 year annualized EPS growth, -1.8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 0.5% speak to its relatively poor ranking.